080210xf's Blog

L'X fragile sera vaincu | Fragile X will be conquered

Addex Pharmaceuticals – PD-LID study go ahead

Jan 07th 2011 – Edison Investment Research today published a report on Addex Pharmaceuticals entitled “PD-LID Study Go Ahead”. In summary, the report says:

Addex will shortly begin enrolment into its key Phase II study of lead product ADX48621 in PD-LID. It is also planning a pilot study of the drug in focal dystonia and evaluating its development in certain other indications including autism and Fragile X syndrome. Meanwhile, partner J&J is gearing up to start its Phase II programme for ADX71149 in schizophrenia, anxiety and potentially other indications. The investment case centres on capturing the value uplift associated with a positive result in the Phase II study of ADX48621 in PD-LID and catalysing a stock market re-rating of the shares by partnering earlier-stage programmes.


No comments yet»

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: